CA2626085A1 - S-omeprazole strontium or hydrate thereof, method for preparing same, and pharmaceutical composition comprising same - Google Patents
S-omeprazole strontium or hydrate thereof, method for preparing same, and pharmaceutical composition comprising same Download PDFInfo
- Publication number
- CA2626085A1 CA2626085A1 CA002626085A CA2626085A CA2626085A1 CA 2626085 A1 CA2626085 A1 CA 2626085A1 CA 002626085 A CA002626085 A CA 002626085A CA 2626085 A CA2626085 A CA 2626085A CA 2626085 A1 CA2626085 A1 CA 2626085A1
- Authority
- CA
- Canada
- Prior art keywords
- strontium
- omeprazole
- hydrate
- mixture
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Abstract
This invention provides S-omeprazole strontium or a hydrate thereof for the prevention or treatment of a gastric acid-related disease, which has high optical purity, theremostability, solubility and nonhygroscopicity, a method for preparing same, and a pharmaceutical composition comprising same.
Claims (23)
1. A S-omeprazole strontium of formula (I):
2. The S-omeprazole strontium of claim 1, which is a crystalline form whose X-ray powder diffraction spectrum shows a major peak having an I/I o value of 100% at 2.theta. of 5.8~0.2.
3. The S-omeprazole strontium of claim 1, which is an amorphous form.
4. A hydrate of S-omeprazole strontium of claim 1.
5. The hydrate of S-omeprazole strontium of claim 4, which is a crystalline form whose X-ray powder diffraction spectrum shows major peaks having I/I o values of at least 3% at 2.theta.~0.2 of 5.6, 11.1, 13.5, 14.8, 16.2, 17.5, 18.0, 20.1, 20.4, 21.2, 22.2, 24.5, 25.2. 26.3, 27.5, 29.8, 31.1, 32.8 and 36.5.
6. The hydrate of S-omeprazole strontium of claim 5, which is represented by formula (IV):
7. The hydrate of S-omeprazole strontium of claim 4, which is a crystalline form whose X-ray powder diffraction spectrum shows a major peak having an I/I o value of 100% at 2.theta. of 25.2~0.2.
8. A method for preparing the crystalline S-omeprazole strontium hydrate of formula (IV), which comprises adding strontium hydroxide to a neutral solution containing S-omeprazole of formula (III) and stirring the resulting mixture:
9. The method of claim 8, wherein the strontium hydroxide is used in an amount ranging 0.5 to 0.75 molar equivalent based on S-omeprazole.
10. The method of claim 8, wherein the neutral solution is prepared by dissolving or suspending S-omeprazole in an organic solvent selected from the group consisting of methanol, ethanol, 1-propanol, 2-propanol, acetonitrile, tetrahydrofuran, acetone and a mixture thereof, or in a mixture of said organic solvent and water.
11. The method of claim 8, wherein the organic solvent is selected from methanol, acetone and a mixture thereof.
12. A method for preparing the crystalline S-omeprazole strontium hydrate of formula (IV), which comprises adding a reactive strontium salt to a basic solution of S-omeprazole of formula (III) containing a base, and stirring the resulting mixture:
13. The method of claim 12, wherein the base is used in an amount ranging from 1 to 3 molar equivalents based on S-omeprazole.
14. The method of claim 12, wherein the reactive strontium salt is used in an amount ranging from 0.5 to 0.75 molar equivalent based on the base.
15. The method of claim 12, wherein the basic solution is prepared by dissolving or suspending S-omeprazole and the base in an organic solvent selected from the group consisting of methanol, ethanol, 1-propanol, 2-propanol, acetonitrile, tetrahydrofuran, acetone and a mixture thereof, or in a mixture of said organic solvent and water.
16. The method of claim 12, wherein the base is selected from the group consisting of lithium hydroxide, sodium hydroxide, potassium hydroxide, ammonia, methylamine, ethylamine, propylamine, dimethylamine, diethylamine, trimethylamine, triethylamine and a mixture thereof.
17. The method of claim 12, wherein the reactive strontium salt is selected from the group consisting of strontium chloride, strontium bromide, strontium sulfate, strontium nitrate, strontium perchlorate, strontium acetate, strontium carbonate, strontium oxalate and a mixture thereof.
18. A pharmaceutical composition for the prevention or treatment of a gastric acid-related disorder, which comprises the S-omeprazole strontium or a hydrate thereof according to claim 1 or 4 as an active ingredient and a pharmaceutically acceptable salt.
19. The composition of claim 18, which is administered in the form of an oral formulation.
20. The composition of claim 19, wherein the amount of the S-omeprazole strontium or hydrate thereof is the range of 0.1 to 95% by weight based on the total composition.
21. The composition of claim 20, wherein the amount of the S-omeprazole strontium or hydrate thereof is the range of 1 to 70% by weight based on the total composition.
22. The composition of claim 18, which is administered in the form of a sterile injectable formulation.
23. The composition of claim 18, wherein the gastric acid-related disorder is gastroesophageal reflux disease, gastroenteritis or gastric ulcer.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20050101059 | 2005-10-26 | ||
| KR10-2005-0101059 | 2005-10-26 | ||
| KR2006000760 | 2006-03-06 | ||
| KRPCT/KR2006/000760 | 2006-03-06 | ||
| PCT/KR2006/004369 WO2007049914A1 (en) | 2005-10-26 | 2006-10-25 | S-omeprazole strontium or hydrate thereof, method for preparing same, and pharmaceutical composition comprising same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2626085A1 true CA2626085A1 (en) | 2007-05-03 |
| CA2626085C CA2626085C (en) | 2011-12-06 |
Family
ID=37967988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2626085A Expired - Fee Related CA2626085C (en) | 2005-10-26 | 2006-10-25 | S-omeprazole strontium or hydrate thereof, method for preparing same, and pharmaceutical composition comprising same |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JP5017274B2 (en) |
| AU (1) | AU2006306906B2 (en) |
| CA (1) | CA2626085C (en) |
| IL (1) | IL190709A (en) |
| MY (1) | MY140986A (en) |
| NO (1) | NO20082358L (en) |
| RU (1) | RU2372345C1 (en) |
| WO (1) | WO2007049914A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7576219B2 (en) | 2005-10-26 | 2009-08-18 | Hanmi Pharm. Co., Ltd | Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8301182D0 (en) * | 1983-03-04 | 1983-03-04 | Haessle Ab | NOVEL COMPOUNDS |
| SE510650C2 (en) * | 1997-05-30 | 1999-06-14 | Astra Ab | New association |
| WO2004099182A1 (en) * | 2003-05-05 | 2004-11-18 | Ranbaxy Laboratories Limited | Zinc salt of (s)-omeprazole |
| ATE386522T1 (en) * | 2003-07-23 | 2008-03-15 | Nycomed Gmbh | ALKALINE SALTS OF PROTON PUMP INHIBITORS |
| RU2007145207A (en) * | 2005-05-06 | 2009-06-20 | Гленмарк Фармасьютикалз Лимитед (In) | ESOMEPRAZOL STRONGTED SALT, METHOD FOR PRODUCING IT AND CONTAINING ITS PHARMACEUTICAL COMPOSITIONS |
-
2006
- 2006-10-25 AU AU2006306906A patent/AU2006306906B2/en not_active Ceased
- 2006-10-25 WO PCT/KR2006/004369 patent/WO2007049914A1/en active Application Filing
- 2006-10-25 RU RU2008120703/04A patent/RU2372345C1/en not_active IP Right Cessation
- 2006-10-25 JP JP2008537592A patent/JP5017274B2/en not_active Expired - Fee Related
- 2006-10-25 CA CA2626085A patent/CA2626085C/en not_active Expired - Fee Related
-
2008
- 2008-04-07 MY MYPI20081014A patent/MY140986A/en unknown
- 2008-04-08 IL IL190709A patent/IL190709A/en not_active IP Right Cessation
- 2008-05-23 NO NO20082358A patent/NO20082358L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP5017274B2 (en) | 2012-09-05 |
| IL190709A0 (en) | 2008-11-03 |
| MY140986A (en) | 2010-02-12 |
| RU2372345C1 (en) | 2009-11-10 |
| CA2626085C (en) | 2011-12-06 |
| AU2006306906B2 (en) | 2010-02-04 |
| WO2007049914A1 (en) | 2007-05-03 |
| IL190709A (en) | 2012-03-29 |
| NO20082358L (en) | 2008-07-25 |
| JP2009513625A (en) | 2009-04-02 |
| AU2006306906A1 (en) | 2007-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2860676T3 (en) | Salts or cocrystals of 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol | |
| ES2694675T3 (en) | Crystalline complex of 1-cyano-2- (4-cyclopropyl-benzyl) -4- (β-D-glucopyranos-1-yl) -benzene, methods for its preparation and use thereof for preparation of medicines | |
| RU2425041C2 (en) | Crystalline and other forms of salts of lactic acid and 4-amino-5-fluorine-3-[6-(4-methylpiperazine-1-yl)-1h-benzimidazole-2-yl]-1h-quinoline-2-one | |
| GEP20105086B (en) | Potassium salt of an hiv integrase inhibitor | |
| CA2943998C (en) | Salt of 1-(2-deoxy-2-fluoro-4-thio-.beta.-d-arabinofuranosyl)cytosine | |
| CA2671816A1 (en) | Salts of imidazole-5-carboxylic acid derivatives, a method for preparing same and pharmaceutical compositions comprising same | |
| RU2010126230A (en) | PYRAZOLE DERIVATIVES MONOSEBACINATE | |
| JP2010090149A5 (en) | ||
| JP2010132669A (en) | STRONTIUM RANELATE ALPHA (alpha)-CRYSTALLINE FORM, METHOD OF PRODUCING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | |
| RU2014143717A (en) | HIGH PURITY CYCLOPEPTIDE CRYSTAL, AND ALSO THE WAY OF ITS PRODUCTION AND ITS APPLICATION | |
| UA86335C2 (en) | S-omeprazole strontium or hydrate thereof, method for preparing same, and pharmaceutical composition comprising same | |
| CN103951634A (en) | Epalrestat salt crystal aquo-complex and hydroxypiperidine eutectic and preparation method and application thereof | |
| RU2016106125A (en) | Salts of Dasatinib in Crystal Form | |
| RU2004129307A (en) | CRYSTALLINE POLYMORPHIC FORM OF IRINOTECAN HYDROCHLORIDE | |
| CA2514373A1 (en) | N-phenylbenzamide derivatives as drugs for the treatment of copd | |
| JP2007519727A5 (en) | ||
| CA2626085A1 (en) | S-omeprazole strontium or hydrate thereof, method for preparing same, and pharmaceutical composition comprising same | |
| CA2595815A1 (en) | Salt form of a dopamine agonist | |
| ES2394688T3 (en) | Precursor phase and its use to prepare the tetrahydrated magnesium salt of an omeprazole enantiomer | |
| CA2643400A1 (en) | Camptothecin derivatives and their uses | |
| RU2005109560A (en) | PHARMACEUTICAL COMPOSITION, INCLUDING SIBUTRAMINE METHANESULPHONATE CRYSTALLINE HEMIDATE | |
| JP2008521874A5 (en) | ||
| CA2679915A1 (en) | Novel sulfonated sugar compound and use thereof as medicine | |
| JP2006517932A5 (en) | ||
| EP3119793B1 (en) | New polymorphs and new solid states of tiacumicin b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20181025 |